Home / Resource Library / Long-term outcomes of the ZUMA-1 study assessing axicabtagene ciloleucel for the treatment of refractory B-cell lymphoma

Long-term outcomes of the ZUMA-1 study assessing axicabtagene ciloleucel for the treatment of refractory B-cell lymphoma

Two year follow up results of a phase II trial of CAR T axicabtagene ciloleucel in relpased DLBCL.